𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Guillain–Barré syndrome after rtPA therapy for acute stroke

✍ Scribed by A. Bersano; D. Santoro; A. Prelle; S. Lanfranconi; M. Ranieri; C. S. Tadeo; N. Bresolin; P. L. Baron

Publisher
Springer Milan
Year
2010
Tongue
English
Weight
377 KB
Volume
31
Category
Article
ISSN
1590-1874

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The acute phase reactant, fibrinogen, as
The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barré syndrome
✍ Rashmi Sanjay; Janice Flanagan; Donata Sodano; Kenneth C. Gorson; Allan H. Roppe 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

The Guillian Barré syndrome is an acute inflammatory disorder for which plasma exchange is effective treatment. Up to 10% relapse after plasma exchange suggesting that treatment sometimes finishes before disease activity has resolved. We studied whether plasma fibrinogen, an inflammatory marker, mig

Novel anti-idiotype antibody therapy for
Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: Use relevant to Guillain-Barré syndrome
✍ S. Usuki; K. Taguchi; S.A. Thompson; P.B. Chapman; R.K. Yu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 574 KB

## Abstract Campylobacteriosis is a frequent antecedent event in Guillain‐Barré syndrome (GBS), inducing high‐titer serum antibodies for ganglioside antigens in the peripheral nervous system (PNS). Molecular mimicry between the lipooligosaccharide (LOS) component of __Campylobacter jejuni__ and hum

CSF protein biomarkers for proximal axon
CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome
✍ A. Petzold; J. Brettschneider; K. Jin; G. Keir; N.M.F. Murray; N.P. Hirsch; Y. I 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 280 KB

## Abstract Early predictors of prognosis in Guillain‐Barré syndrome (GBS) are needed to identify patients who are likely to make a poor recovery and to guide therapeutic decision‐making in the acute phase. Here we investigate whether axonal protein biomarkers released into the cerebrospinal fluid